{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:15Z","timestamp":1759402155660},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00120-022-01815-6","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T13:02:48Z","timestamp":1649250168000},"page":"484-494","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nachsorge von Hodentumoren in der urologischen Praxis\u00a0\u2013 historische Entwicklung und aktuelle Aspekte"],"prefix":"10.1007","volume":"61","author":[{"given":"Klaus-Peter","family":"Dieckmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Guido","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"G\u00fcbitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"W\u00fclfing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"1815_CR1","unstructured":"Bell B (1794) A treatise on the hydrocele, on sacocele, or cancer, and other diseases of the testes. Bell & Bradfute, Edinburgh"},{"key":"1815_CR2","volume-title":"Diagnose und Therapie der malignen Hodentumoren","author":"F K\u00f6rner","year":"1970","unstructured":"K\u00f6rner\u00a0F (1970) Diagnose und Therapie der malignen Hodentumoren. Ferdinand Enke, Stuttgart"},{"key":"1815_CR3","volume-title":"Tumours of the testicle","author":"JP Blandy","year":"1970","unstructured":"Blandy\u00a0JP, Hope-Stone\u00a0HF, Dayan\u00a0AD (1970) Tumours of the testicle. William Heinemann, London"},{"key":"1815_CR4","first-page":"1340","volume":"82","author":"L Weissbach","year":"1985","unstructured":"Weissbach\u00a0L, Boedefeld\u00a0EA, Seeber\u00a0S (1985) Hodentumoren: Fr\u00fchzeitige Diagnose und stadiengerechte Therapie sichern den Erfolg. Dtsch Arztebl 82:1340\u20131349","journal-title":"Dtsch Arztebl"},{"key":"1815_CR5","first-page":"509","volume":"130","author":"HJ Illiger","year":"1988","unstructured":"Illiger\u00a0HJ (1988) Sinn und Unsinn der Tumornachsorge. Munch Med Wochenschr 130:509\u2013513","journal-title":"Munch Med Wochenschr"},{"key":"1815_CR6","first-page":"1","volume":"29","author":"E Grundmann","year":"1988","unstructured":"Grundmann\u00a0E (1988) Wege und Ziele der Tumornachsorge. Internist (Berl) 29:1\u201312","journal-title":"Internist (Berl)"},{"key":"1815_CR7","doi-asserted-by":"publisher","first-page":"CD012425","DOI":"10.1002\/14651858.CD012425.pub2","volume":"2019","author":"BL H\u00f8eg","year":"2019","unstructured":"H\u00f8eg\u00a0BL, Bidstrup\u00a0PE, Karlsen\u00a0RV, Friberg\u00a0AS, Albieri\u00a0V, Dalton\u00a0SO et al (2019) Follow-up strategies following completion of primary cancer treatment in adult cancer survivors. Cochrane Database Syst Rev 2019:CD12425. https:\/\/doi.org\/10.1002\/14651858.CD012425.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1815_CR8","first-page":"163","volume-title":"Therapie der malignen Hodentumoren","author":"H Delbr\u00fcck","year":"1991","unstructured":"Delbr\u00fcck\u00a0H (1991) Nachsorge und Rehabilitation von Patienten mit malignen nicht-seminomat\u00f6sen Hodentumoren. In: Jaeger\u00a0N, R\u00fcther\u00a0U, Scheulen\u00a0ME, Schlegel\u00a0G (Hrsg) Therapie der malignen Hodentumoren. TumorDiagnostik, Leonberg, S 163\u2013174"},{"key":"1815_CR9","first-page":"102","volume":"29","author":"K Erpenbach","year":"1990","unstructured":"Erpenbach\u00a0K, Derschum\u00a0W, Reis\u00a0M, von Vietsch\u00a0H (1990) Ergebnisse einer engmaschigen Hodentumornachsorge. Urologe\u00a0A 29:102\u2013107 (discussion 107\u2013109)","journal-title":"Urologe A"},{"key":"1815_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0093-7754(03)00098-8","volume":"30","author":"GV Kondagunta","year":"2003","unstructured":"Kondagunta\u00a0GV, Sheinfeld\u00a0J, Motzer\u00a0RJ (2003) Recommendations of follow-up after treatment of germ cell tumors. Semin Oncol 30:382\u2013389","journal-title":"Semin Oncol"},{"key":"1815_CR11","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1007\/s00120-005-0881-x","volume":"44","author":"TS Pottek","year":"2005","unstructured":"Pottek\u00a0TS, Dieckmann\u00a0KP (2005) Nachsorge beim Hodentumor lohnt sich. Rezidive sind heilbar. Urologe\u00a0A 44:1024\u20131030","journal-title":"Urologe A"},{"key":"1815_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1055\/s-2008-1068604","volume":"111","author":"C Clemm","year":"1986","unstructured":"Clemm\u00a0C, Berdel\u00a0WE, Hartenstein\u00a0R, Nisenbaum\u00a0J, Fink\u00a0U, Rastetter\u00a0J et al (1986) M\u00fcnchener Nachsorge-Schema bei fortgeschrittenen nichtseminomat\u00f6sen keimzelltumoren. [The Munich follow-up program in advanced non-seminoma testicular tumors. Benefits and costs]. Dtsch Med Wochenschr 111:1181\u20131185","journal-title":"Dtsch Med Wochenschr"},{"key":"1815_CR13","first-page":"33","volume":"27","author":"W H\u00f6ppner","year":"1987","unstructured":"H\u00f6ppner\u00a0W, Hartmann\u00a0M (1987) Besonderheiten in der Nachsorge maligner Hodentumoren. Urologe\u00a0B 27:33\u201337","journal-title":"Urologe B"},{"key":"1815_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00345-004-0441-9","volume":"22","author":"JR Spermon","year":"2004","unstructured":"Spermon\u00a0JR, Witjes\u00a0JA, Kiemeney\u00a0LA (2004) Efficacy of routine follow-up after first-line treatment for testicular cancer. World J Urol 22:235\u2013243","journal-title":"World J Urol"},{"key":"1815_CR15","first-page":"326","volume":"35","author":"KH Sch\u00f6lermann","year":"1996","unstructured":"Sch\u00f6lermann\u00a0KH, Dettmann\u00a0R, Hartmann\u00a0M (1996) Die risikogesteuerte Hodentumornachsorge. Urologe\u00a0A 35:326\u2013330","journal-title":"Urologe A"},{"key":"1815_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/bju.14618","volume":"124","author":"JM Blok","year":"2019","unstructured":"Blok\u00a0JM, Pluim\u00a0I, Daugaard\u00a0G, Wagner\u00a0T, J\u00f3\u017awiak\u00a0K, Wilthagen\u00a0EA et al (2019) Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: A systematic review and meta-analysis. BJU Int 124:424\u2013430","journal-title":"BJU Int"},{"key":"1815_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.urolonc.2017.06.047","volume":"36","author":"F Zengerling","year":"2018","unstructured":"Zengerling\u00a0F, Kunath\u00a0F, Jensen\u00a0K, Ruf\u00a0C, Schmidt\u00a0S, Spek\u00a0A (2018) Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance\u2014A systematic review. Urol Oncol 36:448\u2013458","journal-title":"Urol Oncol"},{"key":"1815_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.289.6456.1423","volume":"289","author":"M Ellis","year":"1984","unstructured":"Ellis\u00a0M, Hartley\u00a0L, Sikora\u00a0K (1984) Value of follow-up of testicular cancer. Br Med\u00a0J 289:1423","journal-title":"Br Med J"},{"key":"1815_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00325481.1988.11700105","volume":"83","author":"B Eiseman","year":"1988","unstructured":"Eiseman\u00a0B, Feiner\u00a0AS (1988) Cost-effective follow-up of the cancer patient. Time for a\u00a0new look. Postgrad Med 83:119\u2013126","journal-title":"Postgrad Med"},{"key":"1815_CR20","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1038\/sj.bjc.6604280","volume":"98","author":"NJ van As","year":"2008","unstructured":"van As\u00a0NJ, Gilbert\u00a0DC, Money-Kyrle\u00a0J, Bloomfield\u00a0D, Beesley\u00a0S, Dearnaley\u00a0DP et al (2008) Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 98:1894\u20131902","journal-title":"Br J Cancer"},{"key":"1815_CR21","first-page":"356","volume":"140","author":"R Cathomas","year":"2010","unstructured":"Cathomas\u00a0R, Helbling\u00a0D, Stenner\u00a0F, Rothermundt\u00a0C, Rentsch\u00a0C, Shahin\u00a0O et al (2010) Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a\u00a0joint effort. Swiss Med Wkly 140:356\u2013369","journal-title":"Swiss Med Wkly"},{"key":"1815_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s001200050452","volume":"40","author":"S Krege","year":"2001","unstructured":"Krege\u00a0S, Schmoll\u00a0HJ, Souchon\u00a0R (2001) Interdisziplin\u00e4rer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Urologe\u00a0A 40:137\u2013147","journal-title":"Urologe A"},{"issue":"Suppl 5","key":"1815_CR23","doi-asserted-by":"publisher","first-page":"v147","DOI":"10.1093\/annonc\/mdq177","volume":"21","author":"HJ Schmoll","year":"2010","unstructured":"Schmoll\u00a0HJ, Jordan\u00a0K, Huddart\u00a0R, Pes\u00a0MP, Horwich\u00a0A, Fizazi\u00a0K et al (2010) Testicular non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v147\u2013v154","journal-title":"Ann Oncol"},{"key":"1815_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s00120-011-2556-0","volume":"50","author":"M Hartmann","year":"2011","unstructured":"Hartmann\u00a0M, Krege\u00a0S, Souchon\u00a0R, De Santis\u00a0M, Gillessen\u00a0S, Cathomas\u00a0R (2011) Nachsorge von Patienten mit Hodentumoren. Interdisziplin\u00e4re evidenzbasierte Empfehlungen. [Follow-up of testicular germ cell cancer patients: Interdisciplinary evidence-based recommendations]. Urologe\u00a0A 50:830\u2013835","journal-title":"Urologe A"},{"key":"1815_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-03931-6","author":"J Busch","year":"2022","unstructured":"Busch\u00a0J, Schmidt\u00a0S, Albers\u00a0P, Heinzelbecker\u00a0J, Kliesch\u00a0S, Lackner\u00a0J et al (2022) Can magnetic resonance imaging replace conventional computerized tomography for follow-up of patients with testicular cancer? A systematic review. World J Urol. https:\/\/doi.org\/10.1007\/s00345-022-03931-6","journal-title":"World J Urol"},{"key":"1815_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2008.10.005","volume":"181","author":"TV Tarin","year":"2009","unstructured":"Tarin\u00a0TV, Sonn\u00a0G, Shinghal\u00a0R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J\u00a0Urol 181:627\u2013632 (discussion 632\u2013633)","journal-title":"J Urol"},{"key":"1815_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.2006.08.4889","volume":"25","author":"GJ Rustin","year":"2007","unstructured":"Rustin\u00a0GJ, Mead\u00a0GM, Stenning\u00a0SP, Vasey\u00a0PA, Aass\u00a0N, Huddart\u00a0RA et\u00a0al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197\u2014the National Cancer Research Institute Testis Cancer Clinical Studies Group. J\u00a0Clin Oncol 25:1310\u20131315","journal-title":"J Clin Oncol"},{"key":"1815_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.euo.2018.08.031","volume":"2","author":"P Chung","year":"2019","unstructured":"Chung\u00a0P, O\u2019Malley\u00a0ME, Jewett\u00a0MAS, Bedard\u00a0PL, Panzarella\u00a0T, Sturgeon\u00a0J et al (2019) Detection of relapse by low-dose computed tomography during surveillance in stage I testicular germ cell tumours. Eur Urol Oncol 2:437\u2013442","journal-title":"Eur Urol Oncol"},{"key":"1815_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01199","author":"JK Joffe","year":"2022","unstructured":"Joffe\u00a0JK, Cafferty\u00a0FH, Murphy\u00a0L, Rustin\u00a0GJS, Sohaib\u00a0SA, Gabe R, et\u00a0al (2022) Imaging modality anf frequency in surveillance of stage\u00a01 seminoma testicular cancer: Results from a\u00a0randomized, phase\u00a0III, noninferiority trial (TRISST). J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.21.01199","journal-title":"J\u00a0Clin Oncol"},{"key":"1815_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.crad.2008.10.011","volume":"64","author":"SA Sohaib","year":"2009","unstructured":"Sohaib\u00a0SA, Koh\u00a0DM, Barbachano\u00a0Y, Parikh\u00a0J, Husband\u00a0JE, Dearnaley\u00a0DP et\u00a0al (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64:362\u2013367","journal-title":"Clin Radiol"},{"key":"1815_CR31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000511245","volume":"105","author":"S Kliesch","year":"2021","unstructured":"Kliesch\u00a0S, Schmidt\u00a0S, Wilborn\u00a0D, Aigner\u00a0C, Albrecht\u00a0W, Bedke\u00a0J et al (2021) Management of germ cell tumours of the testes in adult patients: German clinical practice guideline, PART II\u2014Recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord\/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy. Urol Int 105:181\u2013191","journal-title":"Urol Int"},{"key":"1815_CR32","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","volume":"17","author":"T Gilligan","year":"2019","unstructured":"Gilligan\u00a0T, Lin\u00a0DW, Aggarwal\u00a0R, Chism\u00a0D, Cost\u00a0N, Derweesh\u00a0IH et\u00a0al (2019) Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J\u00a0Natl Compr Canc Netw 17:1529\u20131554","journal-title":"J Natl Compr Canc Netw"},{"key":"1815_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.002","author":"J Oldenburg","year":"2022","unstructured":"Oldenburg\u00a0J, Berney\u00a0DM, Bokemeyer\u00a0C, Climent\u00a0MA, Daugaard\u00a0G, Gietema\u00a0JA et al (2022) Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.002","journal-title":"Ann Oncol"},{"key":"1815_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/annonc\/mdf032","volume":"13","author":"ML Harvey","year":"2002","unstructured":"Harvey\u00a0ML, Geldart\u00a0TR, Duell\u00a0R, Mead\u00a0GM, Tung\u00a0K (2002) Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer\u2014A necessary risk? Ann Oncol 13:237\u2013242","journal-title":"Ann Oncol"},{"key":"1815_CR35","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.eururo.2009.06.029","volume":"57","author":"S Tolan","year":"2010","unstructured":"Tolan\u00a0S, Vesprini\u00a0D, Jewett\u00a0MA, Warde\u00a0PR, O\u2019Malley\u00a0M, Panzarella\u00a0T et\u00a0al (2010) No role for routine chest radiography in stage I seminoma surveillance. Eur Urol 57:474\u2013479","journal-title":"Eur Urol"},{"key":"1815_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejca.2017.07.005","volume":"84","author":"H DeLaPena","year":"2017","unstructured":"DeLaPena\u00a0H, Sharma\u00a0A, Glicksman\u00a0C, Joseph\u00a0J, Subesinghe\u00a0M, Traill\u00a0Z et al (2017) No longer any role for routine follow-up chest x\u2011rays in men with stage I germ cell cancer. Eur J Cancer 84:354\u2013359","journal-title":"Eur J Cancer"},{"key":"1815_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<162::AID-CNCR22>3.0.CO;2-V","volume":"88","author":"JM Trigo","year":"2000","unstructured":"Trigo\u00a0JM, Tabernero\u00a0JM, Paz-Ares\u00a0L, Garcia-Llano\u00a0JL, Mora\u00a0J, Lianes\u00a0P et al (2000) Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 88:162\u2013168","journal-title":"Cancer"},{"key":"1815_CR38","doi-asserted-by":"publisher","first-page":"5030349","DOI":"10.1155\/2019\/","volume":"2019","author":"KP Dieckmann","year":"2019","unstructured":"Dieckmann\u00a0KP, Simonsen-Richter\u00a0H, Kulejewski\u00a0M, Anheuser\u00a0P, Zecha\u00a0H, Isbarn\u00a0H et al (2019) Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment. Biomed Res Int 2019:5030349. https:\/\/doi.org\/10.1155\/2019\/","journal-title":"Biomed Res Int"},{"key":"1815_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.canep.2019.01.001","volume":"59","author":"BD Nicholson","year":"2019","unstructured":"Nicholson\u00a0BD, Jones\u00a0NR, Protheroe\u00a0A, Joseph\u00a0J, Roberts\u00a0NW, Van den Bruel\u00a0A et\u00a0al (2019) The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. Cancer Epidemiol 59:15\u201321","journal-title":"Cancer Epidemiol"},{"key":"1815_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1464-410X.2007.06905.x","volume":"100","author":"R Venkitaraman","year":"2007","unstructured":"Venkitaraman\u00a0R, Johnson\u00a0B, Huddart\u00a0RA, Parker\u00a0CC, Horwich\u00a0A, Dearnaley\u00a0DP (2007) The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 100:30\u201332","journal-title":"BJU Int"},{"key":"1815_CR41","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.18.01480","volume":"37","author":"KP Dieckmann","year":"2019","unstructured":"Dieckmann\u00a0KP, Radtke\u00a0A, Geczi\u00a0L, Matthies\u00a0C, Anheuser\u00a0P, Eckardt\u00a0U et al (2019) Serum levels of microRNA-371a-3p (M371 Test) as a\u00a0new biomarker of testicular germ cell-tumors: Results of a\u00a0prospective multicentric study. J\u00a0Clin Oncol 37:1412\u20131423","journal-title":"J Clin Oncol"},{"key":"1815_CR42","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","volume":"80","author":"R Le\u00e3o","year":"2021","unstructured":"Le\u00e3o\u00a0R, Albersen\u00a0M, Looijenga\u00a0LHJ, Tandstad\u00a0T, Kollmannsberger\u00a0C, Murray\u00a0MJ et al (2021) Circulating MicroRNas, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review. Eur Urol 80:456\u2013466","journal-title":"Eur Urol"},{"key":"1815_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01643-z","author":"CD Fankhauser","year":"2021","unstructured":"Fankhauser\u00a0CD, Christiansen\u00a0AJ, Rothermundt\u00a0C, Cathomas\u00a0R, Wettstein\u00a0MS, Grossmann\u00a0NC et al (2021) Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-021-01643-z","journal-title":"Br J Cancer"},{"key":"1815_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.eururo.2006.05.051","volume":"51","author":"KP Dieckmann","year":"2007","unstructured":"Dieckmann\u00a0KP, Kulejewski\u00a0M, Pichlmeier\u00a0U, Loy\u00a0V (2007) Diagnosis of Contralateral testicular Intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a\u00a0single random biopsy. Eur Urol 51:175\u2013185","journal-title":"Eur Urol"},{"key":"1815_CR45","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/JCO.20.02352","volume":"39","author":"JM Blok","year":"2021","unstructured":"Blok\u00a0JM, Groot\u00a0HJ, Huele\u00a0EH, de Wit\u00a0R, Horenblas\u00a0S, Nuver\u00a0J et al (2021) Dose-dependent effect of platinum-based chemotherapy on the risk of metachronous contralateral testicular cancer. J\u00a0Clin Oncol 39:319\u2013327","journal-title":"J Clin Oncol"},{"key":"1815_CR46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41585-021-00440-w","volume":"18","author":"M Chovanec","year":"2021","unstructured":"Chovanec\u00a0M, Lauritsen\u00a0J, Bandak\u00a0M, Oing\u00a0C, Kier\u00a0GG, Kreiberg\u00a0M et\u00a0al (2021) Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nat Rev Urol 18:227\u2013245","journal-title":"Nat Rev Urol"},{"key":"1815_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/ijc.32704","volume":"147","author":"R Hellesnes","year":"2020","unstructured":"Hellesnes\u00a0R, Kvammen \u00d8, Myklebust\u00a0T\u00c5, Bremnes\u00a0RM, Karlsdottir \u00c1, Negaard\u00a0HFS et al (2020) Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer 147:21\u201332","journal-title":"Int J Cancer"},{"key":"1815_CR48","unstructured":"Leitlinienprogramm Onkologie, Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens, Langversion 1.1. 2019. AWMF-Registernummer: 043\/049OL. https:\/\/www.leit-linienprogramm-onkologie.de\/leitlinien\/hodentumoren. Zugegriffen: 9. Jan. 2022"},{"key":"1815_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","volume":"33","author":"C Kollmannsberger","year":"2015","unstructured":"Kollmannsberger\u00a0C, Tandstad\u00a0T, Bedard\u00a0PL, Cohn-Cedermark\u00a0G, Chung\u00a0PW, Jewett\u00a0MA et al (2015) Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J\u00a0Clin Oncol 33:51\u201357","journal-title":"J Clin Oncol"},{"key":"1815_CR50","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1002\/cncr.27539","volume":"118","author":"D Vesprini","year":"2012","unstructured":"Vesprini\u00a0D, Chung\u00a0P, Tolan\u00a0S, Gospodarowicz\u00a0M, Jewett\u00a0M, O\u2019Malley\u00a0M et\u00a0al (2012) Utility of serum tumor markers during surveillance for stage I seminoma. Cancer 118:5245\u20135250","journal-title":"Cancer"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01815-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01815-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:39:48Z","timestamp":1675197588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01815-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01815-6","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.-P.\u00a0Dieckmann besitzt 9,7\u202f% Anteile der Fa. miRdetect, GmbH, Bremerhaven. C.G.\u00a0Ruf, R.\u00a0G\u00fcbitz, C.\u00a0W\u00fclfing und F.\u00a0Zengerling geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}